StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

Analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Down 0.1 %

Akari Therapeutics stock opened at $0.90 on Monday. Akari Therapeutics has a twelve month low of $0.85 and a twelve month high of $4.40. The stock’s fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.88.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.